X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/nppa-revises-ceiling-prices-of-128-formulations/articleshow/97033906.cms
https://www.globenewswire.com/news-release/2022/06/03/2455957/0/en/OncXerna-Therapeutics-Announces-Upcoming-ASCO-Poster-Featuring-Data-Showing-the-Phase-2-Glioblastoma-Trial-of-Bavituximab-with-Chemoradiation-and-Adjuvant-Temozolomide-Met-its-Prim.html
https://www.clinicaltrialsarena.com/news/epicentrx-paediatric-cns-tumour-treatment/
https://www.businesswire.com/news/home/20201213005052/en/Novocure-Announces-National-Reimbursement-in-Switzerland-for-Optune%C2%AE-in-Combination-With-Temozolomide-for-the-Treatment-of-Newly-Diagnosed-Glioblastoma
https://www.europeanpharmaceuticalreview.com/news/134334/pelareorep-based-combination-therapy-improves-glioblastoma-patient-survival/
https://www.globenewswire.com/news-release/2020/11/23/2131796/0/en/TRACON-Announces-Publication-in-Cancer-Cell-of-Clinical-Data-that-Provides-Molecular-Insight-into-the-Mechanism-of-Action-of-TRC102-and-Patient-Populations-Most-Likely-to-Respond-t.html
https://www.esmo.org/oncology-news/tert-promoter-mutations-may-not-be-indicative-of-sensitivity-to-temozolomide
https://www.prnewswire.com/news-releases/denovo-biopharma-receives-fdas-permission-to-proceed-with-a-biomarker-guided-phase-2b-clinical-trial-with-db102-enzastaurin-in-first-line-treatment-of-glioblastoma-gbm-300939143.html
https://www.biospace.com/article/bristol-myers-squibb-s-opdivo-improves-5-year-survival-in-lung-cancer/?s=95
https://www.raps.org/news-and-articles/news-articles/2019/8/fda-warns-turkish-drugmaker-over-penicillin-cross
https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=6312019105346
https://www.pharmacompass.com/pdf/news/deva-holding-as-on-fda-import-alert-list-1562395165.pdf
https://www.prnewswire.com/news-releases/adastra-pharmaceuticals-announces-positive-interim-data-from-phase-1b-clinical-trial-of-zotiraciclib-in-the-treatment-of-recurrent-malignant-gliomas-300860262.html
https://www.prnewswire.com/news-releases/delmar-provides-clinical-update-on-val-083-from-ongoing-first--and-second-line-trials-in-patients-with-mgmt-unmethylated-glioblastoma-at-a-key-opinion-leader-forum-during-the-american-society-of-clinical-oncology-asco-annual-mee-300860314.html
https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-February-27-2019-1551242597.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-2-2019-1546408718.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-24-2018-1540357479.pdf
https://www.pharmacompass.com/pdf/news/jiangsu-yew-pharmaceutical-co-ltd-fails-edqm-inspection-1537438043.pdf
https://www.businesswire.com/news/home/20180912005524/en/Novocure-Zai-Lab-Announce-Strategic-Collaboration-License
https://www.fiercebiotech.com/research/could-even-more-cancer-patients-benefit-from-parp-inhibitors
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204159
https://www.fiercepharma.com/pharma/can-sanofi-compete-lung-cancer-i-o-med-cemiplumab-it-s-aiming-for-third
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-16-2018-1526446624.pdf
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=206750
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207658
http://www.dddmag.com/article/2017/02/gw-pharmas-cannabis-derived-drug-shows-promise-brain-cancer-study
http://www.fiercepharma.com/manufacturing/mylan-recalling-brain-tumor-drug
http://www.fiercebiotech.com/biotech/abbvie-s-ph2-parp-study-misses-survival-endpoints-hopes-rest-bigger-ph3
http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204639
https://www.pharmacompass.com/pdf/news/approved-new-list-of-candidate-drugs-to-bioisencao-1475582007.pdf
http://www.prnewswire.com/news-releases/amerigen-announces-final-approval-from-fda-for-generic-version-of-temodar-300315449.html
http://www.prnewswire.com/news-releases/mylan-launches-generic-temodar-capsules-300296050.html
http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-announces-successful-completion-of-end-of-phase-2-meeting-with-fda-on-val-083-for-the-treatment-of-refractory-glioblastoma-multiforme-300274779.html
https://www.pharmacompass.com/pdf/news/lotus-pharms-temozolomide-approved-in-us-an-anti-cancer-chemotherapy-drug-1462507628.pdf
https://www.pharmacompass.com/pdf/news/idt-australia-ltds-generic-temozolomide-approved-in-us-as-chemotherapy-drug-1460706669.pdf
https://www.pharmacompass.com/pdf/news/lannett-holdings-generic-temozolomide-approved-in-us-an-oral-chemotherapy-drug-1459160044.pdf
https://www.pharmacompass.com/pdf/news/kremers-urban-pharms-generic-temozolomide-approved-in-us-an-anti-cancer-chemotherapy-drug-1455705717.pdf
http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-present-updated-phase-ii-safety-and-efficacy-data-on-val-083-in-refractory-glioblastoma-multiforme-300174888.html
http://www.in-pharmatechnologist.com/Processing/Merck-recalls-276-000-pill-bottles
http://www.xconomy.com/new-york/2015/05/31/celldex-builds-case-for-brain-cancer-vaccine-with-new-asco-data/
http://indianexpress.com/article/india/india-others/12-cancer-drugs-may-come-under-price-control/
http://ir.delmarpharma.com/press-releases/detail/674/delmar-pharmaceuticals-receives-notice-of-allowance-for
Market Place
Share 
